Showing results (1201-1210 of 6,956) with videos related to
Sort By:
Pageof 696
Journal of Clinical Pharmacology|April 6, 2021
Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset HypophosphatasiaWei-Jian Pan, Rajendra Pradhan, Ryan Pelto, et al.Journal of Clinical Pharmacology|February 1, 1988
The efficacy results and safety profile of imipenem/cilastatin from the clinical research trialsG B Calandra, F M Ricci, C Wang, et al.Journal of Clinical Pharmacology|July 11, 2020
A Survey on Knowledge Gaps in Assessment and Management of Severe Drug Hypersensitivity Reactions: Multicenter Cross-Sectional Study of Australian Health Care ProvidersDaniel Mazzoni, Hui Wen Tee, Sara Lee de Menezes, et al.Journal of Clinical Pharmacology|July 16, 2020
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia DisorderBojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.Journal of Clinical Pharmacology|August 11, 2020
Enhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical RecordEmma M Tillman, Sarah L Suppes, Keith Feldman, et al.Journal of Clinical Pharmacology|April 24, 2021
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer PatientsSven Stodtmann, Silpa Nuthalapati, Doerthe Eckert, et al.Journal of Clinical Pharmacology|May 1, 1986
Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentrations and antiarrhythmic effectA A Holazo, R K Brazzell, W A ColburnJournal of Clinical Pharmacology|May 1, 1986
Inhibition of tolbutamide elimination by cimetidine but not ranitidineE W Cate, J F Rogers, J R PowellJournal of Clinical Pharmacology|April 5, 2023
A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary InterventionHui Wu, Shaobin JiaJournal of Clinical Pharmacology|April 12, 2023
Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseYanbin Zeng, Xiaohui Guo, Fengjiao Xiao, et al.Pageof 696